"Der Schwerpunkt unserer Praxis liegt in der Diagnostik und Behandlung von Blut- und Tumorerkrankungen. In der Regel werden Sie von Ihrem Hausarzt oder einem Krankenhaus zu uns überwiesen. Viele Lebensbereiche werden von der Krankheit berührt. Unsere Aufgabe ist es, die erforderlichen Maßnahmen selbst durchzuführen oder zu koordinieren. Bei uns erwartet Sie von Anfang an eine persönliche Betreuung durch einen medizinischen Ansprechpartner. Die Behandlung findet im engen fachlichen Austausch mit Ihrem Arzt des Vertrauens statt.Unser Spezialistenteam bildet sich regelmäßig fachlich weiter, deshalb sind Sie bei uns in guten Händen und können mit der bestmöglichen Betreuung rechnen."

During the past decade, Hämatologisch-Onkologische Praxis Würselen conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hämatologisch-Onkologische Praxis Würselen" #1 sponsor was "AIO-Studien-gGmbH" with 3 trials, followed by "iOMEDICO AG" with 2 trials sponsored, "Genentech, Inc." with 1 trials sponsored, "Hoffmann-La Roche" with 1 trials sponsored and "University Hospital Tuebingen" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hämatologisch-Onkologische Praxis Würselen" #1 collaborator was "Roche Pharma AG" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator and "Crolll Gmbh" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Hämatologisch-Onkologische Praxis Würselen" are "Metastatic Breast Cancer" (2 trials), "Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC" (1 trials), "Advanced Solid Tumors or Hematologic Malignancies" (1 trials), "CD20+ Aggressive B-Cell Lymphoma" (1 trials) and "Carcinoma, Non-Small-Cell Lung" (1 trials). Many other conditions were trialed in "Hämatologisch-Onkologische Praxis Würselen" in a lesser frequency.

Most popular intervention types in "Hämatologisch-Onkologische Praxis Würselen" are "Drug" (6 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Bevacizumab" (1 trials), "Carboplatin" (1 trials), "Conventional Vincristine" (1 trials) and "Docetaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hämatologisch-Onkologische Praxis Würselen" are 8 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hämatologisch-Onkologische Praxis Würselen". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Hämatologisch-Onkologische Praxis Würselen, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hämatologisch-Onkologische Praxis Würselen, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".